https://www.europesays.com/1888321/ Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch #ABSCIENCE #america #AmyotrophicLateralSclerosis #BreakthroughTreatment #EuronextParis #InflammatoryDiseases #MastCells #microglia #MultipleSclerosis #neuroinflammation #Parkinson'sDisease #PATRICKVERMERSCH #science #technology #UnitedStates #UnitedStatesOfAmerica #US #USA